240 related articles for article (PubMed ID: 23463086)
1. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
3. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
5. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
[TBL] [Abstract][Full Text] [Related]
6. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
7. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
[TBL] [Abstract][Full Text] [Related]
8. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
[TBL] [Abstract][Full Text] [Related]
9. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
10. [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
Gómez-Ramírez J; Martín-Pérez E; Amat CG; Sanz IG; Bermejo E; Rodríguez A; Larrañaga E
Cir Esp; 2010 Dec; 88(6):404-12. PubMed ID: 20971458
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
13. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
14. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
[TBL] [Abstract][Full Text] [Related]
15. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Morris-Stiff G; Tan YM; Vauthey JN
Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid as a marker of sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy for colorectal liver metastases: don't forget the tumor.
Rahbari NN; Weitz J
Ann Surg Oncol; 2013 May; 20(5):1405-7. PubMed ID: 23463087
[No Abstract] [Full Text] [Related]
17. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
18. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Khan AZ; Morris-Stiff G; Makuuchi M
J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
20. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
